INSR and non-small cell lung carcinoma: Accordingly, it is recognized that multiple kinase inhibitors developed towards IGF-1R also target InsR (reviewed in [14, 15, 20]) while monoclonal antibodies are more specific towards IGF-1R but may as a consequence of IGF-1R internalization and degradation also alter hybrid IGF-1R:InsR expression in NSCLC and other tumor cells [19, 20, 25, 44].